Pharmaids Pharmaceuticals Limited

PHARMAID

INE117D01018

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 06:00:54 2024-05-31 am EDT			5-day change	1st Jan Change
53.71 ^INR	-0.63%		-9.91%	+10.33%

May. 28	Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
May. 28	Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Pharmaids Pharmaceuticals Limited Announces Resignation of Dasi Reddy Rakesh as Executive Director

November 20, 2020 at 05:18 am EST

Pharmaids Pharmaceuticals Limited received a resignation from Mr. Dasi Reddy Rakesh from the position of Executive Director of the company vide its letter dated 20 November, 2020 due to the pre-occupied with other engagements and the board has accepted the resignation with effect from 20 November, 2020 in the board meeting held on November 20, 2020.

Latest news about Pharmaids Pharmaceuticals Limited

Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 28	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	May. 28	CI
Pharmaids Pharma Completes Acquisition of Adita Bio Sys	Mar. 04	MT
Pharmaids Pharmaceuticals Limited completed the acquisition of 99.86% stake in Adita Bio Sys Private Ltd.	Mar. 01	CI
Pharmaids Pharmaceuticals Limited announced that it has received INR 525.448343 million in funding from Asian Hotels Limited, Tumkur Trade Center Private Limited and another investors	Mar. 01	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Pharmaids Pharmaceuticals Names Chairman; Shares Slip 5%	Feb. 12	MT
Pharmaids Pharmaceuticals Buys Additional 1.25% Stake in Anugraha Chemicals	Feb. 09	MT
Pharmaids Pharmaceuticals Limited Appoints Shankarappa Nagaraja Vinaya Babu as Non-Executive Non-Independent Director and Chairman	Jan. 31	CI
Pharmaids Pharmaceuticals Limited agreed to acquire 99.86% stake in Adita Bio Sys Private Ltd. for INR 530 million.	Jan. 06	CI
Pharmaids Pharmaceuticals Limited Approves the Appointment of Dr. Prasad S as Chief Executive Officer	Jan. 06	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 11	CI
Pharmaids Pharmaceuticals Limited Announces Board Changes	23-08-29	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-04	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	23-05-29	CI
Pharmaids Pharmaceuticals Limited Announces Change in Registered Office Address	23-05-23	CI
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-02-13	CI
Pharmaids Pharmaceuticals to Acquire Majority Stake in Anugraha Chemicals	23-01-25	MT
Pharmaids Pharmaceuticals Limited Announces Vyasmurti Madhavrao Shingatgeri Resigned from the Post of Independent Director of the Company	23-01-23	CI
Pharmaids Pharmaceuticals Approves Appointment of Pattamadai Natarajasarma Vijay as an Independent Director	23-01-03	CI
Pharmaids Pharmaceuticals to Raise $2 Million via Equity Offering; Shares Jump 7%	22-11-29	MT
Pharmaids Pharmaceuticals Limited Approves Resignation of Veerareddy Vallapureddy as Independent Director	22-11-29	CI
Pharmaids Pharmaceuticals Limited announced that it expects to receive INR 168 million in funding	22-11-28	CI
Pharmaids Pharmaceuticals Swings to Loss in Fiscal Q2	22-11-23	MT
Pharmaids Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-09	CI

Chart Pharmaids Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Pharmaids Pharmaceuticals Limited is an India-based suppliers of a range of specialty chemicals, skin care, hospital care and generic products in the areas of orthopedic, neuro and gastro, and other. The Company is engaged in the business of trading and manufacturing of generics, bulk drugs and intermediaries, and other. The Company operates through a single segment, Drug Formulations. Its specialty chemicals products include Retino!, DL Alpha Tocopherol, D Pantothenate, Cyanocobalamin, Pyridoxine Hcl, Thiamine, Nicotinic Acid, Water Sol. Vitamin E, Coenzyme Q10 and D-Biotin. Its skin care products include Best care hands, Hands Sanitizer, Moisturizing Cream, Skinsure Plus, SkinSure Ultra, Alcohol Gel and Barrier Cream. Its hospital care products include Xepi Rub M, Facein Spray, Sod Hypochlorite, Sanmedin, Strumen G, Strumen TRIACID, Facein Eco, Facein Power 256, Facein Spray, Sod Hypochlorite, Wipes and PPE. Its generic products include Linzomust, Benfoshine, Amplimmune and other.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PHARMAIDS PHARMACEUTICALS LIMITED	+10.33%	22.7M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
NOVARTIS AG	+9.78%	210B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B